Immunomedics Inc (IMMU) Gross Profit Margin starting from the second quarter 2020 to second quarter 2019, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Immunomedics Inc   (NASDAQ: IMMU)


Immunomedics Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IMMU Gross Profit Margin (Jun 30 2020)
Q2 		(Mar 31 2020)
Q1 		(Dec 31 2019)
Q4 		(Sep 30 2019)
Q3 		(Jun 30 2019)
Q2
Y / Y Revenue Change -
Seq. Revenue Change -
Revenue In Millions $20.07
Gross Profit Margin 91.69 %
Gross Profit Margin Total Ranking # 217
Gross Profit In Millions $18.41
Y / Y Gross Profit Change -
Seq. Gross Profit Change -


Commenting Second Quarter 2020 Gross Profit Margin



Observing second quarter 2020 results within In Vitro & In Vivo Diagnostic Substances industry only one other company has achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from to 217.
Learn about Gross Margin
IMMU's Gross Profit Margin second quarter 2020 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 2
Healthcare Sector # 43
Overall # 209

Gross Profit Margin Statistics
High Average Low
99.89 % 84.54 % 16.86 %
(Jun 30 2018)   (Dec 31 2017)


IMMU Gross Income Trends • More of IMMU's Profitabilty Ratios • IMMU Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
IMMU's Cumulative Gross Profit Margin
In Vitro & In Vivo Diagnostic Substances Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
IMMU's Gross Profit Margin Profitability versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for IMMU's Competitors
Gross Profit Margin Profit Margin for Immunomedics Inc 's Suppliers
Gross Profit Margin Profit Margin for IMMU's Customers

You may also want to know
IMMU's Annual Growth Rates IMMU's Profitability Ratios IMMU's Asset Turnover Ratio IMMU's Dividend Growth
IMMU's Roe IMMU's Valuation Ratios IMMU's Financial Strength Ratios IMMU's Gross Profit Growth
IMMU's Roa IMMU's Inventory Turnover Ratio IMMU's Growth Rates IMMU's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Jun 30 2020, within In Vitro & In Vivo Diagnostic Substances Industry Gross Profit MarginJun 30 2020 MRQ Gross ProfitJun 30 2020 MRQ Revenue
Navidea Biopharmaceuticals Inc   99.87 %$ 0.271  Millions$ 0.271  Millions
Immunomedics Inc   91.69 %$ 18.405  Millions$ 20.074  Millions
Quidelortho Corp  73.73 %$ 148.751  Millions$ 201.754  Millions
Meridian Bioscience Inc   65.87 %$ 55.852  Millions$ 84.797  Millions
Myriad Genetics Inc   65.45 %$ 61.000  Millions$ 93.200  Millions
Oxford Immunotec Global Plc  62.81 %$ 3.665  Millions$ 5.835  Millions
Idexx Laboratories Inc  59.50 %$ 379.342  Millions$ 637.592  Millions
Alpha Teknova Inc   57.40 %$ 3.469  Millions$ 6.044  Millions
Ortho Clinical Diagnostics Holdings Plc  48.04 %$ 187.600  Millions$ 390.500  Millions
Neogen Corporation  47.43 %$ 51.729  Millions$ 109.074  Millions
Immucell Corporation  43.27 %$ 1.283  Millions$ 2.966  Millions
Quotient Limited  39.33 %$ 3.510  Millions$ 8.924  Millions
Lantheus Holdings Inc   39.16 %$ 25.848  Millions$ 66.010  Millions
Heska Corporation  39.08 %$ 17.865  Millions$ 45.712  Millions
Biomerica Inc   26.92 %$ 0.734  Millions$ 2.725  Millions
Aspira Women s Health inc   20.51 %$ 0.153  Millions$ 0.746  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.